Cargando…

Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial

Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloch, Yehudit, Belmaker, R. H., Shvartzman, Pesach, Romem, Pnina, Bolotin, Arkady, Bersudsky, Yuly, Azab, Abed N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460750/
https://www.ncbi.nlm.nih.gov/pubmed/34556722
http://dx.doi.org/10.1038/s41598-021-98245-9
_version_ 1784571821264207872
author Bloch, Yehudit
Belmaker, R. H.
Shvartzman, Pesach
Romem, Pnina
Bolotin, Arkady
Bersudsky, Yuly
Azab, Abed N.
author_facet Bloch, Yehudit
Belmaker, R. H.
Shvartzman, Pesach
Romem, Pnina
Bolotin, Arkady
Bersudsky, Yuly
Azab, Abed N.
author_sort Bloch, Yehudit
collection PubMed
description Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014).
format Online
Article
Text
id pubmed-8460750
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-84607502021-09-27 Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial Bloch, Yehudit Belmaker, R. H. Shvartzman, Pesach Romem, Pnina Bolotin, Arkady Bersudsky, Yuly Azab, Abed N. Sci Rep Article Oxygen enriched air may increase oxygen pressure in brain tissue and have biochemical effects even in subjects without lung disease. Consistently, several studies demonstrated that normobaric oxygen treatment has clinical benefits in some neurological conditions. This study examined the efficacy of normobaric oxygen treatment in subjects with depression. In a randomized, double-blind trial, 55 participants aged 18–65 years with mild to moderate depression (had a Hamilton Rating Scale for Depression [HRSD] score of ≥ 8) were recruited to the study from the Southern district in Israel. Participants underwent a psychiatric inclusion assessment at baseline and then were randomly assigned to either normobaric oxygen treatment of 35% fraction of inspired oxygen or 21% fraction of inspired oxygen (room air) through a nasal tube, for 4 weeks, during the night. Evaluations were performed at baseline, 2 and 4 weeks after commencement of study interventions, using the following tools: HRSD; Clinical Global Impression (CGI) questionnaire; World Health Organization-5 questionnaire for the estimation of Quality of Life (WHO-5-QOL); Sense of Coherence (SOC) 13-item questionnaire; and, Sheehan Disability Scale (SDS). A multivariate regression analysis showed that the mean ± standard deviation [SD] changes in the HRSD scores from baseline to week four were − 4.2 ± 0.3 points in the oxygen-treated group and − 0.7 ± 0.6 in the control group, for a between-group difference of 3.5 points (95% confidence interval [CI] − 5.95 to − 1.0; P = 0.007). Similarly, at week four there was a between-group difference of 0.71 points in the CGI score (95% CI − 1.00 to − 0.29; P = 0.001). On the other hand, the analysis revealed that there were no significant differences in WHO-5-QOL, SOC-13 or SDS scores between the groups. This study showed a significant beneficial effect of oxygen treatment on some symptoms of depression. Trial registration: NCT02149563 (29/05/2014). Nature Publishing Group UK 2021-09-23 /pmc/articles/PMC8460750/ /pubmed/34556722 http://dx.doi.org/10.1038/s41598-021-98245-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bloch, Yehudit
Belmaker, R. H.
Shvartzman, Pesach
Romem, Pnina
Bolotin, Arkady
Bersudsky, Yuly
Azab, Abed N.
Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_full Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_fullStr Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_full_unstemmed Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_short Normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
title_sort normobaric oxygen treatment for mild-to-moderate depression: a randomized, double-blind, proof-of-concept trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460750/
https://www.ncbi.nlm.nih.gov/pubmed/34556722
http://dx.doi.org/10.1038/s41598-021-98245-9
work_keys_str_mv AT blochyehudit normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT belmakerrh normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT shvartzmanpesach normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT romempnina normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT bolotinarkady normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT bersudskyyuly normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial
AT azababedn normobaricoxygentreatmentformildtomoderatedepressionarandomizeddoubleblindproofofconcepttrial